A Study to Evaluate the Safety and Tolerability of ARV-806 in Adults with Advanced Cancer that has the KRAS G12D Mutation

2025-521062-10-00 Protocol ARV-806-101 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 2 EU/EEA countries · 6 sites · Protocol ARV-806-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 149
Countries 2
Sites 6

KRAS G12D Mutated Advanced Solid Tumors

Key facts

Sponsor
Arvinas Operations Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2026-03-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-521062-10-00
ClinicalTrials.gov
NCT07023731

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

KRAS G12D Mutated Advanced Solid Tumors

VersionLevelCodeTermSystem organ class
28.0 LLT 10069759 KRAS mutation 10018065
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Arvinas Operations Inc.

Sponsor organisation
Arvinas Operations Inc.
Address
5 Science Park
City
New Haven
Postcode
06511-1966
Country
United States

Scientific contact point

Organisation
Arvinas Operations Inc.
Contact name
Executive Medical Director, Clinical Development - Oncology

Public contact point

Organisation
Arvinas Operations Inc.
Contact name
Senior Vice President, Global Regulatory Affairs

Locations

2 EU/EEA countries · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Authorised, recruitment pending 14 2
Spain Authorised, recruitment pending 37 4
Rest of world
United States
98

Investigational sites

Italy

2 sites · Authorised, recruitment pending
Centro Ricerche Cliniche Di Verona S.r.l.
UOS di Terapie Sperimentali in Oncologia, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
Azienda Ospedaliero Universitaria Pisana
UO Oncologia Medica 2, Via Roma 67, 56126, Pisa

Spain

4 sites · Authorised, recruitment pending
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Clinica Universidad De Navarra
Medical Oncology, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Clinico Universitario De Valencia
Medical Oncology, Phase I Unit, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitari Vall D Hebron
Medical Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-30 Italy Acceptable
2026-03-09
2026-03-12